[Strategies for antimigraine agents].
Ishii
Taketoshi
T
ishii.taketoshi@mn.mt-pharma.co.jp
Taniguchi
Hiroyuki
H
Saito
Akira
A
D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D019274:Botulinum Toxins, Type A; D015740:Calcitonin Gene-Related Peptide / Q000037:antagonists & inhibitors; D002540:Cerebral Cortex; D002560:Cerebrovascular Circulation; D015195:Drug Design; D004353:Drug Evaluation, Preclinical; D004878:Ergotamine / Q000627:therapeutic use; D018691:Excitatory Amino Acid Antagonists; D006801:Humans; D008881:Migraine Disorders / Q000188:drug therapy* / Q000209:etiology*; D019001:Nitric Oxide Synthase / Q000037:antagonists & inhibitors; D017470:Receptors, Glutamate; D058825:Serotonin 5-HT1 Receptor Agonists; D017366:Serotonin Receptor Agonists / Q000627:therapeutic use; D014276:Trigeminal Nerve; D014363:Tryptamines / Q000627:therapeutic use; D014664:Vasodilation
D000894:Anti-Inflammatory Agents, Non-Steroidal; D018691:Excitatory Amino Acid Antagonists; D017470:Receptors, Glutamate; D058825:Serotonin 5-HT1 Receptor Agonists; D017366:Serotonin Receptor Agonists; D014363:Tryptamines; D019001:Nitric Oxide Synthase; D019274:Botulinum Toxins, Type A; D015740:Calcitonin Gene-Related Peptide; D004878:Ergotamine